糖皮质激素和(或)免疫球蛋白治疗替罗非班诱导重度血小板减少症的临床观察

郭世杰; 齐向前

doi:10.13201/j.issn.1001-1439.2021.05.006

糖皮质激素和(或)免疫球蛋白治疗替罗非班诱导重度血小板减少症的临床观察

郭世杰,
齐向前^,

- 泰达国际心血管病医院内二科(天津,300457)

详细信息

通讯作者: 齐向前,E-mail:qixq@tedaich.com

中图分类号: R541.4

收稿日期: 2020-11-29

Glucocorticoid and/or immunoglobulin were used to treat severe thrombocytopenia induced by tirofiban

GUO Shijie,
QI Xiangqian^,

- Department of Internal Medicine, TEDA International Cardiovascular Hospital, Tianjin, 300457, China

More Information

Corresponding author: QI Xiangqian, E-mail: qixq@tedaich.com

Received Date: 29 November 2020

摘要

摘要: 目的:观察糖皮质激素和(或)免疫球蛋白治疗替罗非班诱导产生的重度血小板减少症的临床疗效。方法:回顾性收集2008年9月—2016年11月在我院心脏内科住院期间出现的19例替罗非班诱导产生重度血小板减少症患者的基本临床资料、糖皮质激素及免疫球蛋白用法用量、血小板计数、血小板计数减少期间出血事件,依据是否使用糖皮质激素和(或)免疫球蛋白将患者分成3组:单独使用糖皮质激素者为治疗组1,共6例;2种药均使用者为治疗组2,共4例;2种药均未使用者为对照组,共9例。比较血小板计数最低值、每日增长幅度、治疗后恢复至正常范围所需时间、各种出血事件发生比例在3组间的差异。结果:3组患者基本临床资料差异无统计学意义(P>0.05);血小板计数基线值、最低值、每日增长幅度及治疗后恢复至正常范围所需时间在3组间的差异均无统计学意义(P>0.05);3组间各种出血事件发生比例差异也无统计学意义(P>0.05)。结论:糖皮质激素和(或)免疫球蛋白治疗替罗非班诱导产生的重度血小板减少症无明确改善效果。
- 替罗非班 /
- 血小板减少症 /
- 糖皮质激素 /
- 免疫球蛋白
Abstract: Objective: To observe the clinical efficacy of glucocorticoid and/or immunoglobulin in the treatment of severe thrombocytopenia induced by tirofiban.Methods: We collected 19 cases with severe thrombocytopenia retrospectively from September 2008 to November 2016 in our hospital. We divided the patients into three groups: the use of glucocorticoid alone in group 1 with 6 cases; the use of glucocorticoid and immunoglobulin in group 2 with 4 cases; the use of none in group 3 with 9 cases, as control. Form them we detected glucocorticoid or immunoglobulin usage and dosage, changes in the platelet count, bleeding during the event. The minimum platelet count, daily increase, time returned to normal range after treatment, and the proportion of various bleeding events were compared among the three groups.Results: There was no statistical significance in the basic clinical data of 3 groups(P>0.05). There were no significant differences in baseline value, minimum value, daily increase range of platelet count and the time returned to normal range after treatment among the three groups(P>0.05). There was no significant difference in the proportion of various bleeding events among the 3 groups(P>0.05).Conclusion: Glucocorticoid and/or immunoglobulin have no clear effect on the treatment of severe thrombocytopenia induced by tirofiban.
- tirofiban /
- thrombocytopenia /
- glucocorticoid /
- immunoglobulin

HTML全文

参考文献(10)

[1]	胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.
[2]	胡大一,韩雅玲,孙艺红,等.替罗非班在冠状动脉粥样硬化性心脏病治疗的中国专家共识[J].中华内科杂志,2013,52(5):434-439.
[3]	The RESTORE Investigators.Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[J].Circulation,1997,96(5):1445-1453.
[4]	Lo GK,Juhl D,Warkentin TE,et al.Evaluation of pretest clinical score(4 T's)for the diagnosis of heparin-induced thrombocytopenia in two clinical settings[J].J Thromb Haemost,2006,4(4):759-765.
[5]	中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华糖尿病杂志,2014,6(7):447-498.
[6]	中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华心血管病杂志,2011,39(7):579-616.
[7]	Schulman S,Kearon C.Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients[J].J Thromb Haemost,2005,3(4):692-694.
[8]	Schulman S,Kearon C,Kakkar AK,et al.Extended use of dabigatran,warfarin,or placebo in venous thrombnembolism[J].N Engl J Med,2013,368(8):709-718.
[9]	李月平,周玉杰,刘宇扬,等.经皮冠状动脉介入治疗术后替罗非班诱发极重度血小板减少症二例[J].中国介入心脏病学杂志,2006,14(5):315.
[10]	李红,贾若飞,贺建勋,等.替罗非班诱导血小板减少症临床观察及干预分析[J].中国介入心脏病学杂志,2019,27(5):265-270.